MCID: NRR001
MIFTS: 46

Neuroretinitis

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Neuroretinitis

MalaCards integrated aliases for Neuroretinitis:

Name: Neuroretinitis 12 15 72
Juxtapapillary Focal Retinitis and Retinochoroiditis 12 72
Retinitis 44 72
Focal Retinitis and Retinochoroiditis, Juxtapapillary 12
Papilloretinitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10176
MeSH 44 D012173
ICD10 33 H30.9
UMLS 72 C0035333 C0154874 C3665438

Summaries for Neuroretinitis

MalaCards based summary : Neuroretinitis, also known as juxtapapillary focal retinitis and retinochoroiditis, is related to retinal hemangioblastoma and cancer-associated retinopathy. An important gene associated with Neuroretinitis is CD40LG (CD40 Ligand), and among its related pathways/superpathways is A-beta Pathways: Uptake and Degradation. The drugs Prednisone and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include retina, eye and testes, and related phenotypes are hematopoietic system and immune system

Wikipedia : 75 Cat-scratch disease (CSD) is an infectious disease that results from a scratch or bite of a cat.... more...

Related Diseases for Neuroretinitis

Diseases related to Neuroretinitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2810)
# Related Disease Score Top Affiliating Genes
1 retinal hemangioblastoma 33.5 VEGFA CA2
2 cancer-associated retinopathy 30.7 VEGFA RCVRN
3 myelitis 30.7 MOG AQP4
4 hydrops, lactic acidosis, and sideroblastic anemia 30.6 VEGFA AQP4
5 retinal artery occlusion 30.4 VEGFA ACE
6 relapsing-remitting multiple sclerosis 30.4 MOG IFNB1 AQP4
7 central nervous system disease 29.8 MOG IFNB1 AQP4
8 acute disseminated encephalomyelitis 29.8 MOG AQP4
9 systemic scleroderma 29.8 MLN CD40LG ACE
10 optic nerve disease 29.6 MOG IFNB1 DPYSL5 AQP4
11 demyelinating disease 29.4 MOG IFNB1 CD40LG AQP4
12 nervous system disease 29.2 VEGFA MOG IFNB1 AQP4 ACE
13 autoimmune optic neuritis 28.7 RCVRN MOG DPYSL5 AQP4
14 retinitis pigmentosa 3 12.6
15 retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities 12.6
16 retinitis pigmentosa 12 12.6
17 retinitis pigmentosa 27 12.6
18 retinitis pigmentosa 7 12.6
19 doyne honeycomb retinal dystrophy 12.6
20 retinitis pigmentosa 50 12.5
21 retinitis pigmentosa 2 12.5
22 retinitis pigmentosa 10 12.5
23 retinitis pigmentosa 11 12.5
24 retinitis pigmentosa 41 12.5
25 retinitis pigmentosa 67 12.5
26 retinitis pigmentosa 9 12.5
27 retinitis pigmentosa 1 12.5
28 retinitis pigmentosa 14 12.5
29 retinitis pigmentosa 38 12.5
30 late-onset retinal degeneration 12.5
31 retinitis pigmentosa 13 12.5
32 retinitis pigmentosa 17 12.5
33 retinitis pigmentosa 28 12.5
34 retinitis pigmentosa 25 12.5
35 retinitis pigmentosa 18 12.5
36 retinitis pigmentosa 19 12.5
37 retinitis pigmentosa 30 12.5
38 retinitis pigmentosa 26 12.5
39 retinitis pigmentosa 20 12.5
40 retinitis pigmentosa 33 12.5
41 retinitis pigmentosa 31 12.5
42 retinitis pigmentosa 36 12.5
43 retinitis pigmentosa 40 12.5
44 retinitis pigmentosa 35 12.5
45 retinitis pigmentosa 46 12.5
46 retinitis pigmentosa 57 12.5
47 retinitis pigmentosa 69 12.5
48 retinitis pigmentosa 43 12.5
49 retinitis pigmentosa 23 12.5
50 retinitis pigmentosa 42 12.5

Graphical network of the top 20 diseases related to Neuroretinitis:



Diseases related to Neuroretinitis

Symptoms & Phenotypes for Neuroretinitis

MGI Mouse Phenotypes related to Neuroretinitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.56 ACE AQP4 CD40LG FLNA IFNB1 MOG
2 immune system MP:0005387 9.32 ACE AQP4 CA2 CD40LG FLNA IFNB1

Drugs & Therapeutics for Neuroretinitis

Drugs for Neuroretinitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 232)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Azithromycin Approved Phase 4 83905-01-5 447043 55185
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
5
Pancrelipase Approved, Investigational Phase 4 53608-75-6
6
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
7 Antineoplastic Agents, Hormonal Phase 4
8 Sildenafil Citrate Phase 4 171599-83-0
9 Citrate Phase 4
10 Antibodies Phase 4
11 Immunoglobulins Phase 4
12 Gastrointestinal Agents Phase 4
13 Autoantibodies Phase 4
14 pancreatin Phase 4
15 Phosphodiesterase Inhibitors Phase 4
16 Phosphodiesterase 5 Inhibitors Phase 4
17 Vasodilator Agents Phase 4
18 Vardenafil Dihydrochloride Phase 4
19
Eplerenone Approved Phase 2, Phase 3 107724-20-9 150310 443872
20
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
21
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
22
Acyclovir Approved Phase 3 59277-89-3 2022
23
Ganciclovir Approved, Investigational Phase 2, Phase 3 82410-32-0 3454
24
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
25
Lutein Approved, Investigational, Nutraceutical Phase 3 127-40-2 6433159
26
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
27
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
28 Tocotrienol Investigational Phase 3 6829-55-6
29 Hormones Phase 2, Phase 3
30 Hormone Antagonists Phase 2, Phase 3
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
32 Natriuretic Agents Phase 2, Phase 3
33 diuretics Phase 2, Phase 3
34 Diuretics, Potassium Sparing Phase 2, Phase 3
35 Mineralocorticoids Phase 2, Phase 3
36 Mineralocorticoid Receptor Antagonists Phase 2, Phase 3
37 Immunologic Factors Phase 3
38 Antibodies, Monoclonal Phase 2, Phase 3
39 Antineoplastic Agents, Immunological Phase 2, Phase 3
40 retinol Phase 3
41 Retinol palmitate Phase 3
42 Calciferol Phase 3
43 Bone Density Conservation Agents Phase 3
44 Tocotrienols Phase 3
45 Tocopherols Phase 3
46 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
47 Ganciclovir triphosphate Phase 2, Phase 3
48 Antihypertensive Agents Phase 3
49 Isopropyl unoprostone Phase 3
50
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743

Interventional clinical trials:

(show top 50) (show all 253)
# Name Status NCT ID Phase Drugs
1 Open Label Study of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
2 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
3 Role of Capsular Tension Ring in Anterior Capsular Contraction in Retinitis Pigmentosa Patients Completed NCT00717080 Phase 4
4 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
5 Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000894 Phase 4 Cidofovir;Probenecid;Ganciclovir
6 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
7 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
8 Correlation of Functional and Structural Outcomes With Serum Antibody Profiles in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial Completed NCT02843490 Phase 4 Ranibizumab
9 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
10 Pharmacokinetics of Valganciclovir in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4 Valganciclovir
11 An Integrated Approach With Vardenafil Orodispersible and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV) Completed NCT02450188 Phase 4 Vardenafil
12 Open-Label Safety Study of Valganciclovir in Patients With CMV Retinitis and AIDS Who Have Complications Due to IV Treatment Unknown status NCT00017784 Phase 3 Valganciclovir
13 A Randomized, Double-masked, Placebo Controlled Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
14 Foscarnet-Ganciclovir CMV Retinitis Trial Completed NCT00000136 Phase 3 Foscarnet;Ganciclovir
15 A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00000688 Phase 3 Ganciclovir
16 Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis Completed NCT00002070 Phase 3 Sargramostim;Ganciclovir
17 A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes Completed NCT00002377 Phase 3 Valganciclovir;Ganciclovir
18 Cytomegalovirus Retinitis Retreatment Trial Completed NCT00000134 Phase 3 Ganciclovir;Foscarnet
19 Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT) Completed NCT00000142 Phase 2, Phase 3 Cidofovir
20 Monoclonal Antibody CMV Retinitis Trial (MACRT) Completed NCT00000135 Phase 2, Phase 3 MSL-109
21 A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis Completed NCT00000698 Phase 3 Ganciclovir
22 Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000143 Phase 3 Cidofovir intravenous
23 Ganciclovir Implant Study for Cytomegalovirus Retinitis Completed NCT00000118 Phase 3
24 Randomized Clinical Trial for Retinitis Pigmentosa Completed NCT00346333 Phase 3 Lutein
25 Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa Completed NCT00000114 Phase 3 Vitamin E;Vitamin A
26 Randomized Trial for Retinitis Pigmentosa Completed NCT00000116 Phase 3 Vitamin A;Nutritional Supplement
27 A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay Completed NCT00006145 Phase 3 Valganciclovir
28 An Investigator Initiated Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Valganciclovir in Prevention of Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation Completed NCT00330018 Phase 3 Valganciclovir;Acyclovir
29 A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR) Recruiting NCT03116113 Phase 2, Phase 3
30 The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Patients With Retinitis Pigmentosa Recruiting NCT01680510 Phase 2, Phase 3
31 A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301] Active, not recruiting NCT00999609 Phase 3
32 Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Not yet recruiting NCT03586284 Phase 2, Phase 3 Valganciclovir Hydrochloride;Ganciclovir Sodium;Placebo Oral Tablet;Topical placebo
33 Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period Terminated NCT01786395 Phase 3 UF-021;Placebo
34 Argus® II Retinal Stimulation System Feasibility Protocol Unknown status NCT00407602 Phase 2
35 An Open Labeled Clinical Study to Evaluate the Safety and Efficacy OF Autologous Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Retinitis Pigmentosa. It is Self Funded (Patients' Own Funding) Clinical Trial Unknown status NCT01914913 Phase 1, Phase 2
36 Prospective Non-randomised Exploratory Study to Assess the Safety and Efficacy of Aflibercept (Eylea) in Cystoid Macular Oedema (CMO) Associated With Retinitis Pigmentosa (RP) Unknown status NCT02661711 Phase 2 Aflibercept
37 Dexamethasone in Retinitis Pigmentosa Cystoid Macular Edema Unknown status NCT02804360 Phase 2
38 A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection Completed NCT00002169 Phase 2 Nelfinavir mesylate
39 Nerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II Trial Completed NCT02609165 Phase 2 rhNGF 180 µg/ml eye drops solution;vehicle eye drops
40 Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa Completed NCT01399515 Phase 2 Valproic Acid
41 A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00002437 Phase 2 Cidofovir;Probenecid
42 A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) Completed NCT00000836 Phase 2 Sevirumab
43 An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa Completed NCT00661479 Phase 1, Phase 2 400 µg Brimonidine Tartrate Implant;200 µg Brimonidine Tartrate Implant;100 µg Brimonidine Tartrate Implant
44 CMV Retinitis Retreatment Trial Completed NCT00000766 Phase 2 Foscarnet sodium;Ganciclovir
45 An Open-Label Study of the Safety and Efficacy of Intravitreal ISIS 2922 in Acquired Immune Deficiency Syndrome (AIDS) Patients With Cytomegalovirus Retinitis (NOTE: Restricted to Patients Who Rollover From Another Controlled ISIS 2922 Trial) Completed NCT00002356 Phase 2 Fomivirsen sodium
46 A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR ) Completed NCT00002156 Phase 2 Fomivirsen sodium;Ganciclovir
47 A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa Completed NCT01233609 Phase 2 Valproic Acid;Placebo
48 A Prospective, Multicenter, Open-Label, Single-Arm Study of the Safety and Tolerability of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP) Completed NCT02320812 Phase 1, Phase 2
49 Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis Completed NCT00004794 Phase 2 cidofovir
50 A Phase II, Double-Masked, Randomized, Placebo-Controlled Evaluation of Standard Therapy vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (MSL 109) in the Therapy of AIDS Patients With Cytomegalovirus (CMV) Retinitis Completed NCT00001061 Phase 2 Sevirumab;Foscarnet sodium;Ganciclovir

Search NIH Clinical Center for Neuroretinitis

Cochrane evidence based reviews: retinitis

Genetic Tests for Neuroretinitis

Anatomical Context for Neuroretinitis

MalaCards organs/tissues related to Neuroretinitis:

41
Retina, Eye, Testes, Bone, T Cells, Bone Marrow, Kidney

Publications for Neuroretinitis

Articles related to Neuroretinitis:

(show top 50) (show all 11999)
# Title Authors PMID Year
1
Novel ophthalmic formulation of myriocin: implications in retinitis pigmentosa. 38
30883241 2019
2
The combination of whole-exome sequencing and clinical analysis allows better diagnosis of rare syndromic retinal dystrophies. 38
30925032 2019
3
Atypical herpes simplex virus type 2 acute retinal necrosis presentation with large subretinal lesion. 38
31304428 2019
4
Role of PASCAL and optical coherence tomography angiograpgy in the treatment of diffuse unilateral subacute neuroretinitis caused by large live motile worm. 38
31436212 2019
5
Identification of CRB1 mutations in two Chinese consanguineous families exhibiting autosomal recessive retinitis pigmentosa. 38
31322236 2019
6
The association between cone density and visual function in the macula of patients with retinitis pigmentosa. 38
31172265 2019
7
Altered airway ciliary orientation in patients with X-linked retinitis pigmentosa. 38
31110053 2019
8
Atypical posterior pole retinitis. 38
31245654 2019
9
Fungal retinitis following influenza virus type A (H1N1) infection. 38
31436207 2019
10
Spectral optical coherence tomography findings in an adult patient with syphilitic bilateral posterior uveitis and unilateral punctate inner retinitis. 38
31211286 2019
11
Targeted deletion of Crb1/Crb2 in the optic vesicle models key features of leber congenital amaurosis 8. 38
31145883 2019
12
Utility of en-face imaging in diagnosis of occult macular dystrophy with RP1L1 mutation: A case series. 38
31193770 2019
13
The development and spontaneous resolution of a full-thickness macular hole in bartonella henselae neuroretinitis in a 12-year-old boy. 38
31341998 2019
14
Commentary: Role of PASCAL and optical coherence tomography angiograpgy in the treatment of diffuse unilateral subacute neuroretinitis caused by large live motile worm. 38
31436213 2019
15
Mechanisms of neurodegeneration in a preclinical autosomal dominant retinitis pigmentosa knock-in model with a RhoD190N mutation. 38
30976840 2019
16
The urokinase-type plasminogen activator system as drug target in retinitis pigmentosa: New pre-clinical evidence in the rd10 mouse model. 38
31251468 2019
17
The molecular chaperone Hsp90α deficiency causes retinal degeneration by disrupting Golgi organization and vesicle transportation in photoreceptors. 38
31408169 2019
18
A case of X-linked retinoschisis with atypical fundus appearance. 38
31006083 2019
19
Disease mechanisms and neuroprotection by tauroursodeoxycholic acid in Rpgr knockout mice. 38
30924157 2019
20
Mitochondrial Membrane Protein Associated Neurodegeneration   (MPAN) with a Novel C19orf12 Mutation in the First Decade of Life. 38
30825065 2019
21
A new rhodopsin R135W mutation induces endoplasmic reticulum stress and apoptosis in retinal pigment epithelial cells. 38
30635925 2019
22
Enhanced Depth Navigation Through Augmented Reality Depth Mapping in Patients with Low Vision. 38
31375713 2019
23
Inherited retinal disease in Norway - a characterization of current clinical and genetic knowledge. 38
31429209 2019
24
Tunicamycin-induced photoreceptor atrophy precedes degeneration of retinal capillaries with minimal effects on retinal ganglion and pigment epithelium cells. 38
31421136 2019
25
Dissociation of HKII in retinal epithelial cells induces oxidative stress injury in the retina. 38
31432102 2019
26
Characterizing variants of unknown significance in rhodopsin: A functional genomics approach. 38
30977563 2019
27
The uPAR System as a Potential Therapeutic Target in the Diseased Eye. 38
31426601 2019
28
Genetic testing in patients with retinitis pigmentosa: Features of unsolved cases. 38
30977268 2019
29
A lymphoma patient with Cytomegalovirus retinitis and post-autologous hematopoietic cell transplantation immune reconstitution uveitis: A case report and review of the literature. 38
31033155 2019
30
Visual prognosis, clinical features, and predisposing factors in non-HIV patients with cytomegalovirus retinitis. 38
30030661 2019
31
Systematic review and meta-synthesis of coping with retinitis pigmentosa: implications for improving quality of life. 38
31409325 2019
32
Prevalence of cystoid macular oedema, epiretinal membrane and cataract in retinitis pigmentosa. 38
30291136 2019
33
Projection-Resolved Optical Coherence Tomographic Angiography of Retinal Plexuses in Retinitis Pigmentosa. 38
30849344 2019
34
Genomic Landscape of Sporadic Retinitis Pigmentosa: Findings from 877 Spanish Cases. 38
30902645 2019
35
C3- and CR3-dependent microglial clearance protects photoreceptors in retinitis pigmentosa. 38
31209071 2019
36
VAC14 syndrome in two siblings with retinitis pigmentosa and neurodegeneration with brain iron accumulation. 38
31387860 2019
37
Comparison of structural progression between ciliopathy and non-ciliopathy associated with autosomal recessive retinitis pigmentosa. 38
31370859 2019
38
Functional characterization of CEP250 variant identified in nonsyndromic retinitis pigmentosa. 38
30998843 2019
39
Multimodal Analysis of Hyperautofluorescent Ring Size in Retinitis Pigmentosa. 38
31415695 2019
40
Pediatric roots of cytomegalovirus recurrence and memory inflation in the elderly. 38
31062089 2019
41
Barriers in utilisation of low vision assistive products. 38
31388131 2019
42
The influence of visual field position induced by a retinal prosthesis simulator on mobility. 38
31147839 2019
43
Two-photon polymerized poly(caprolactone) retinal cell delivery scaffolds and their systemic and retinal biocompatibility. 38
31055121 2019
44
Intra- and interspecies comparison of EYS transcripts highlights its characteristics in the eye. 38
31120796 2019
45
Botany, traditional uses, phytochemistry, pharmacology and toxicology of Ilex pubescens Hook et Arn. 38
31401319 2019
46
The expanding phenotype of OFD1-related disorders: Hemizygous loss-of-function variants in three patients with primary ciliary dyskinesia. 38
31373179 2019
47
Pathogenic variants in MT-ATP6: A United Kingdom-based mitochondrial disease cohort study. 38
31187502 2019
48
Significant Vision Recovery after Early Treatment of Diffuse Unilateral Subacute Neuroretinitis. 38
31383398 2019
49
Combined Cytomegalovirus and Herpes Simplex Virus-related Neuroretinitis in an Immunocompetent Patient. 38
31389219 2019
50
Leber's idiopathic stellate neuroretinitis: diagnostic and therapeutic conflicts. 38
31053369 2019

Variations for Neuroretinitis

Expression for Neuroretinitis

Search GEO for disease gene expression data for Neuroretinitis.

Pathways for Neuroretinitis

Pathways related to Neuroretinitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.13 CD40LG ACE

GO Terms for Neuroretinitis

Cellular components related to Neuroretinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 VEGFA RNASE3 MLN IFNB1 FLNA CD40LG
2 external side of plasma membrane GO:0009897 8.92 MOG CD40LG AQP4 ACE

Biological processes related to Neuroretinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 B cell proliferation GO:0042100 9.16 IFNB1 CD40LG
2 kidney development GO:0001822 9.13 VEGFA CA2 ACE
3 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 8.62 VEGFA ACE

Molecular functions related to Neuroretinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.13 VEGFA IFNB1 CD40LG
2 ribonuclease activity GO:0004540 8.62 SAMHD1 RNASE3

Sources for Neuroretinitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....